The age of four-price HPV vaccination has been extended to women aged 9-45

, Dec. 5 (Xinhua Chen Jing) Cervical cancer is one of the most common gynaecological malignancies, the world's 15-44 years old women in the second highest incidence of cancer. Persistent infection with high-risk HPV virus is the main cause of cervical cancer. Previously, the WHO recommended that women between the ages of 9 and 14 who have not had sex be the main people vaccinated against HPV.
Fudan University affiliated obstetrics and gynecology hospital
, the director of doctors, professors, doctoral tutors Hua Keqin 5 interview with reporters expressed deep agreement. For women aged 15-44, cervical cancer is the second-largest malignant tumour, says Prof Wakqin. More than 85 per cent of deaths occur in low- and middle-income countries. The number of new cases of cervical cancer in China is large, rising and younger.
It is learned that the four-priced human papillomavirus vaccine (brewing yeast) (the "four-price HPV vaccine") produced by well-known multinational pharmaceutical companies has been approved by China's State Drug Administration to expand the age of vaccination to 9-45 years old, still using three doses of immunization procedures. The four-priced HPV vaccine is suitable for the prevention of cervical cancer, stage 2 and stage 3 cervical epithelial endoblastoma-like lesions (CIN2/3) and cervical in-place adenocarcinoma (AIS) due to high-risk HPV type 16/18, as well as stage 1 cervical epithelial endoblastoma-like lesions (CIN1).
Li Zhengqing, vice president and general manager of China Research and Development Center, a well-known multinational pharmaceutical company, also said in an interview: "Cervical cancer is a preventable disease, and vaccines are an economical and effective means of disease prevention and control." The first peak in the age-by-age distribution of HPV infection rates among Chinese women is between the ages of 17 and 24, so HPV vaccination among adolescent female populations can help reduce the incidence of HPV infection and cervical cancer in the entire Chinese female population.
at the Women's Cervical Health Knowledge Sharing Society, 99.7 percent of cervical cancer is associated with HPV in the reproductive tract. Protection in sexual behavior is very important. 17-24 years old and 40-44 years old are the two peak age groups for HPV infection in Chinese women. She shared knowledge about women's cervical health, including early diagnosis, early treatment and prevention of cervical cancer.
On 17 November this year, the World Health Organization issued the Global Strategy for the Accelerated Elimination of Cervical Cancer: if the three measures of vaccination, screening and treatment are successfully implemented, more than 40 per cent of new cases and 5 million related deaths could be reduced by 2050.Professor Wei Lihui, lead researcher of the
four-price HPV vaccine China Phase 3 clinical trial on protective effectiveity and safety, and former director of obstetrics and gynecology at Peking University People's Hospital, said: "The four-price HPV vaccine was approved in May 2017 for women aged 20-45 years. Through sustained efforts, just three years later, it was approved in November 2020 for women aged 9-19 years, which is significant. This not only means that we have an added weapon to protect adolescent girls from HPV infection, but also echoes the World Health Organization's Global Strategy to Accelerate the Elimination of Cervical Cancer. Professor
Hua Keqin said that at the time, the Chinese people do not have enough knowledge of cervical cancer prevention and treatment, and the awareness of active screening is not strong. She suggested that contact bleeding, irregular vaginal bleeding, abnormal white belt secretion must be paid attention to in a timely manner. Wakqin introduced the three-level prevention of cervical cancer, the first level of prevention is the vaccination of preventive, which has become a national strategy. (Complete)